

Cerezyme and VPRIV

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form to Priority Partners, toll-free at 1-866-212-4756** to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: Same as Requesting Provider	ider
Name:	NPI#:
Fax:	Phone:
Rendering Provider Info: Same as Referring Provider	
Name:	NPI#:
Fax:	Phone:
accepted compendia, and/or e	ts in accordance with FDA-approved labeling, evidence-based practice guidelines.
Required Demographic Information:	
Patient Weight:kg	
Patient Height:cm	
Drug Information:	
Strength/Measure	Units □ ml □ Gm □ mg □ ea □ Un
	Route of administration
Dosing frequency	
Site of Service Questions: A. Indicate the site of service requested: ☐ On Campus Outpatient Hospital ☐ Home based setting, skip to Criteria Questions ☐ Ambulatory infusion site, skip to Criteria Question	☐ Off Campus Outpatient Hospital ☐ Community office, skip to Criteria Questions
B. Is the patient less than 18 years of age? ☐ Yes, skip to Clinical Criteria Questions ☐ No	
Has the patient experienced an adverse event with the requested product that has not responded to convention	

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC Cerezyme, VPRIV SGM – 07/2023.

interventions (eg acetaminophen, steroids, diphenhydramine, fluids, other pre- medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or

D.	seizures) during or immediately after an infusion? <i>ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation</i> . \square Yes, <i>skip to Clinical Criteria Questions</i> \square No
Е.	Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment? **ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.** Description: Description:
F.	Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? <i>ACTION REQUIRED: If 'Yes'</i> , <i>please attach supporting clinical documentation</i> . Yes, <i>skip to Clinical Criteria Questions</i> No
G.	Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? <i>ACTION REQUIRED: If</i> 'Yes', please attach supporting clinical documentation. Yes, skip to Clinical Criteria Questions \(\sigma\) No
H.	Has the patient's home been deemed not eligible or appropriate for home infusion services by a home infusion provider? <i>ACTION REQUIRED: If 'Yes'</i> , <i>please attach supporting clinical documentation</i> . ☐ Yes, <i>skip to Clinical Criteria Questions</i> ☐ No
I.	Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? **ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.
Cr	iteria Questions:
1	A. What is the prescribed drug?
I	3. What is the ICD-10 code?
1.	. What is the diagnosis?
	☐ Gaucher disease (If checked, go to 2)
	☐ Other, please specify (If checked, go to 2)
g sı	Was the diagnosis of Gaucher disease confirmed by an enzyme assay demonstrating a deficiency of beta- ducocerebrosidase (glucosidase) enzyme activity or by genetic testing? <i>ACTION REQUIRED</i> : If Yes, attach apporting chart note(s) or test results. Yes (If checked, go to 3) No (If checked, go to 3)
3	. Which variant of Gaucher disease does the patient have?
	Type 1 (If checked, go to 4)
	Type 2 (If checked, go to 4)
	7) Po = (11 elicentes), 80 to 1)
	Type 3 (If checked, go to 4)

rescriber or Authorized Signature	Date (mm/dd/yy)
nformation is available for review if requested by Priority Par	
attest that this information is accurate and true, and that doc	umentation supporting this
Greater than 100 kg (220.5 lbs) (If checked, no further ques	tions)
☐ Less than or equal to 100 kg (220.5 lbs) (If checked, <i>no furtion</i>	
6. What is the patient's body weight?	
☐ No (If checked, go to 6)	
Tyes (If checked, go to 6)	
requested drug?	
5. Is the patient experiencing an inadequate response or any int	olerable adverse events from therapy with
☐ No (If checked, go to 6)	
☐ Yes (If checked, go to 5)	